ITRealms:
ITREALMS ... everything news digitally!
Short URLs:
goo.gl,
mcaf.ee,
cli.gs
A team of American and British scientists have
for the first time discovered genetic connections between sleep disturbance and
a range of medical disorders including obesity, reports ITRealms.
Lead author Dr Jacqueline Lane, postdoctoral
fellow at Massachusetts General Hospital (MGH) and joint senior authors Richa
Saxena, Assistant Professor of Anaesthesia at the MGH and Harvard Medical
School and Dr Martin K Rutter, Senior Lecturer in Cardiometabolic Medicine from
The University of Manchester, publish their ground-breaking research in Nature
Genetics today.
The study looked at the biological controllers of
sleep duration, insomnia and excessive daytime sleepiness, and how they linked
to the health and life histories of more than 112,000 people taking part in the
world-leading UK Biobank study.
Study participants reported their sleep duration,
the degree of insomnia and daytime sleepiness, and then had their genes mapped.
Other information about them such as their weight and any diseases they
suffered from was also collected.
The researchers identified for the first time
areas of the genome that are associated with sleep disturbance including
insomnia and excessive daytime sleepiness and also discovered novel genetic
links with several medical conditions including restless legs syndrome,
schizophrenia and obesity.
The strongest genetic association for insomnia
symptoms fell within a gene previously linked to restless legs syndrome – a
nervous system disorder affecting around 1 in 20 people that leads to a strong
urge to move one's legs which is often worse at night. Other gene regions were
important for insomnia but selectively in either men or women.
The team also identified genetic links between
longer sleep duration and schizophrenia risk and between increased levels of
excessive daytime sleepiness and measures of obesity (body mass index and waist
circumference).
The research also suggested that insomnia has
shared underlying biology with major depression and abnormal glucose
metabolism.
Funded by the US National Institutes of Health
and The University of Manchester’s Research Innovation Fund, the study marks a
major advance in our understanding of the biology of sleep.
One in four British adults are obese, according
to the UN Food and Agriculture Organisation, prompting fears that the UK has
become the "fat man of Europe". And at any one time about 280,000
people are being treated for schizophrenia by the NHS. Sufferers have a 1 in 10
chance of dying by their own hand within ten years of diagnosis.
Dr Rutter said: “This clinical science is an
important step forwards in understanding the biological basis for these
conditions so it’s very exciting.
“Scientists have long observed a connection
between sleep disorders and these conditions in epidemiological studies. But
this is the first time these biological links have been identified at a
molecular level.”
UK Biobank aims to improving the prevention,
diagnosis and treatment of a wide range of serious and life-threatening
illnesses.
Dr Lane said ”We’re particularly pleased to be
able to use UK Biobank data in this way; it’s an amazing resource for
scientists.”
Dr Saxena said: “It’s important to remember there
is no molecular targeting available for conditions which affect sleep: all we
really have are sedatives.
“So we hope that this research will enable
scientists to develop new ways to intervene on a range of conditions in a much
more fundamental way.
“We do acknowledge these findings will need
further study, but believe this knowledge amounts to a key advance in our
understanding of the biology behind sleep - a major influence on our health and
behaviour.”
ITREALMS ... everything news digitally!
No comments:
Post a Comment